OBJECTIVE: to investigate the impact of frailty on the utilisation of antithrombotics and on clinical outcomes in older people with atrial fibrillation (AF). DESIGN: prospective study of a cohort of 220 acute inpatients aged > or =70 years with AF, admitted to a teaching hospital in Sydney, Australia (April-July 2007), with 207 followed up over 6 months. RESULTS: a total of 140 patients (64%) were identified as frail using a validated tool. Frail patients were less likely to receive warfarin than non-frail on hospital admission (P = 0.002) and discharge (P < 0.001). During hospitalisation, the proportion of frail participants prescribed warfarin decreased by 10.7% and that of non-frail increased by 6.3%. Over the 6-month follow-up, 43 major or severe haemorrhages (20.8%), 20 cardioembolic strokes (9.7%) and 40 deaths (19.2%) were reported. Compared to non-frail, frail participants were significantly more likely to experience embolic stroke (RR 3.5, 95% CI 1.0-12.0, P < 0.05), had a small non-significant increase in risk of major haemorrhage (RR 1.5, 95% CI = 0.7-3.0, P = 0.29) and had greater mortality (RR 2.8, 95% CI 1.2-6.5, P = 0.01). CONCLUSION: frail older inpatients with AF are significantly less likely to receive warfarin than non-frail and appear more vulnerable to adverse clinical outcomes, with and without antithrombotic therapy.
OBJECTIVE: to investigate the impact of frailty on the utilisation of antithrombotics and on clinical outcomes in older people with atrial fibrillation (AF). DESIGN: prospective study of a cohort of 220 acute inpatients aged > or =70 years with AF, admitted to a teaching hospital in Sydney, Australia (April-July 2007), with 207 followed up over 6 months. RESULTS: a total of 140 patients (64%) were identified as frail using a validated tool. Frail patients were less likely to receive warfarin than non-frail on hospital admission (P = 0.002) and discharge (P < 0.001). During hospitalisation, the proportion of frail participants prescribed warfarin decreased by 10.7% and that of non-frail increased by 6.3%. Over the 6-month follow-up, 43 major or severe haemorrhages (20.8%), 20 cardioembolic strokes (9.7%) and 40 deaths (19.2%) were reported. Compared to non-frail, frail participants were significantly more likely to experience embolic stroke (RR 3.5, 95% CI 1.0-12.0, P < 0.05), had a small non-significant increase in risk of major haemorrhage (RR 1.5, 95% CI = 0.7-3.0, P = 0.29) and had greater mortality (RR 2.8, 95% CI 1.2-6.5, P = 0.01). CONCLUSION: frail older inpatients with AF are significantly less likely to receive warfarin than non-frail and appear more vulnerable to adverse clinical outcomes, with and without antithrombotic therapy.
Authors: Mara A McAdams-DeMarco; Andrew Law; Jingwen Tan; Cassandra Delp; Elizabeth A King; Babak Orandi; Megan Salter; Nada Alachkar; Niraj Desai; Morgan Grams; Jeremy Walston; Dorry L Segev Journal: Transplantation Date: 2015-04 Impact factor: 4.939
Authors: F Panza; V Solfrizzi; V Frisardi; S Maggi; D Sancarlo; F Adante; G D'Onofrio; D Seripa; A Pilotto Journal: J Nutr Health Aging Date: 2011-08 Impact factor: 4.075
Authors: Alexander Bennett; Danijela Gnjidic; Mark Gillett; Peter Carroll; Slade Matthews; Kristina Johnell; Johan Fastbom; Sarah Hilmer Journal: Drugs Aging Date: 2014-03 Impact factor: 3.923
Authors: Alejandra Gullón; Francesc Formiga; Jesús Díez-Manglano; José María Mostaza; José María Cepeda; Antonio Pose; Jesús Castiella; Carmen Suárez-Fernández Journal: Intern Emerg Med Date: 2018-09-06 Impact factor: 3.397
Authors: Claire Johnston; Sarah N Hilmer; Andrew J McLachlan; Slade T Matthews; Peter R Carroll; Carl M Kirkpatrick Journal: Eur J Clin Pharmacol Date: 2014-02-14 Impact factor: 2.953